Pharmaceutical

Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis

China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis.

Feb 11, 2025 - 06:00
Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis
China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis.
Read the original article

Tags:

Previous Article

Public health strategies skip patients with rare diseases, says UK study

Next Article

Fourth person receives eGenesis’ gene-edited pig kidney transplant

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cosmo Pharmaceuticals sees highest patent filings and g...

Dec 10, 2023

Expansive investigation into Stanford president’s past research will be ‘substantially complete’ by mid-July

Expansive investigation into Stanford president’s past ...

May 1, 2023

Orion sees highest patent filings and grants during May in Q2 2024

Orion sees highest patent filings and grants during May...

Jul 22, 2024